FDA chief Gottlieb's departure might not actually be a good thing for vaping industry

  • 📰 CNBC
  • ⏱ Reading Time:
  • 51 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 72%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Some have called FDA Commissioner Scott Gottlieb's resignation a boon for the e-cigarette industry. It may prove more complicated.

Some have called Food and Drug Administration Commissioner Scott Gottlieb's resignation a boon for the e-cigarette industry, which Gottlieb has repeatedly attacked for fueling a surge in teen vaping.

Gottlieb's threats pushed Juul, the company he blames for the teen vaping"epidemic," to halt sales of most of its flavors and shutter its social media accounts. In February, he accused Juul of going back on its word after the San Francisco-based start-up took a $12.8 billion investment from Marlboro maker Altria, and he called the CEOs of both companies to his office.

"He could have [reversed the application extension], he could have tried to pull flavors from the market. So certainly his words were the issue and not always his actions," said Gregory Conley, president of the American Vaping Association, a group that lobbies for"sensible" regulation of vaping products.

"The information on how helpful e-cigarettes are in people trying to quit and how harmful or not they are for young people is a moving target, and it's always hard to set policy in an environment in which you're dealing with one or more moving targets," she said.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 12. in İD

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Biotech stocks fall after FDA chief Scott Gottlieb resignsThe IBB, an ETF that tracks biotech's biggest players, was down more than 2 percent Wednesday, on pace for its worst day since February 7 when it lost 2.5 percent. because the new person isn't going to look past the negative health impacts
Sumber: CNBC - 🏆 12. / 72 Baca lebih lajut »